Erica Underwood, APRN
Family · St Petersburg, FLNPI 1932653839
Payments from drug & device makers
Across 95 payments — averaging $24.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$450
- Sanofi$254
- AbbVie$216
- Regeneron Healthcare Solutions, Inc.$161
- Novartis$151
- Incyte Corporation$151
- plus $955 from 16 others
What the payments were for
- Food & beverage$2,07989%
- Education$25911%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 16 | $450 |
| Sanofi | 8 | $254 |
| AbbVie | 10 | $216 |
| Regeneron Healthcare Solutions, Inc. | 7 | $161 |
| Novartis | 7 | $151 |
| Incyte Corporation | 3 | $151 |
| Amgen | 6 | $149 |
| UCB, Inc. | 5 | $137 |
| Sun Pharmaceutical Industries Inc. | 4 | $110 |
| Arcutis Biotherapeutics, Inc. | 6 | $102 |
| E.r. Squibb & Sons, L.L.C. | 4 | $90 |
| Pfizer | 4 | $74 |
| Almirall LLC | 4 | $69 |
| Lilly USA, LLC | 1 | $35 |
| Hill Dermaceuticals, Inc. | 1 | $34 |
| LEO Pharma Inc. | 1 | $33 |
| Dermavant Sciences, Inc. | 2 | $33 |
| Verrica Pharmaceuticals Inc. | 1 | $24 |
| Fidia Pharma USA Inc. | 1 | $20 |
| Strata Skin Sciences, Inc. | 1 | $18 |
| Mayne Pharma Commercial LLC | 2 | $14 |
| Galderma Laboratories, L.p. | 1 | $13 |
How this compares
$2,338 in reported general payments places this provider in the 80th percentile of 14,618 family providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluorouracil | 54 | $4,454 |
| Clobetasol Propionate | 60 | $2,149 |
| Doxycycline Hyclate | 54 | $1,206 |
| CiclopiroxCiclopirox Olamine | 44 | $962 |
| Triamcinolone Acetonide | 99 | $866 |
| Ketoconazole | 61 | $688 |
| ValacyclovirValacyclovir Hcl | 31 | $675 |
| Tacrolimus | 11 | $366 |
| Fluocinonide | 12 | $363 |
| Hydrocortisone | 60 | $298 |
| Clindamycin Phosphate | 22 | $251 |
| Mupirocin | 18 | $89 |
Paid to pharmacies, not to this prescriber.
Other family in St Petersburg
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
- David RodriguezHialeah$658K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.